Aurora St. Luke's Medical Center Gynecologic Oncology — Milwaukee, Wisconsin

Aurora St. Luke's Medical Center Gynecologic Oncology is a clinical research site located in Milwaukee, Wisconsin, United States 53215.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Aurora St. Luke's Medical Center Gynecologic Oncology has participated in 1 clinical trials.

Therapeutic areas: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Sponsors: Celgene.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Milwaukee

Browse all research sites in Wisconsin · View every site in Milwaukee

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Aurora St. Luke's Medical Center Gynecologic Oncology?

Aurora St. Luke's Medical Center Gynecologic Oncology has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Aurora St. Luke's Medical Center Gynecologic Oncology conducted?

Aurora St. Luke's Medical Center Gynecologic Oncology has 1 clinical trials on record. Their work covers Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Is Aurora St. Luke's Medical Center Gynecologic Oncology accredited by Crixeo Clinical Trials?

Aurora St. Luke's Medical Center Gynecologic Oncology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Aurora St. Luke's Medical Center Gynecologic Oncology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.